The foundation

Our Team

MIORG brings together scientific leadership, clinical insight, business strategy, and board-level guidance to advance patient-derived immuno-oncology programs toward partnering-ready assets.

Our philosophy

Focused expertise across science, medicine, business, and governance helps MIORG translate resistance biology into therapeutic and diagnostic programs.

Board of Directors

Board of Directors.

Founder, CEO & Board Member
Bio

He brings the founder’s scientific thesis to MIORG’s board-level decisions, aligning corporate development with the company’s patient-derived immuno-oncology strategy.

Board Member
Bio

She contributes board-level perspective on strategic partnerships, stakeholder engagement, and the organisational foundations required to build MIORG for long-term collaboration.

Clinical Advisory Board

Clinical and Translational Medicine Advisory Board.

Clinical Advisor (UK and EU)
Bio

He is Professor of Immuno-Oncology at the University of Liverpool, an Honorary Consultant Medical Oncologist in Liverpool, and an Adjunct Professor at the La Jolla Institute for Immunology. His career spans translational cancer immunology, melanoma and ocular-melanoma services, and the design of early-phase trials in solid cancers. That depth keeps MIORG’s preclinical choices connected to clinically answerable questions.

Clinical Advisor (USA)
Bio

He is Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute, as well as the Roy J. and Tara Zuckerberg Professor in Medical Oncology at Hofstra/Northwell. A recognised leader in rare melanoma and early-phase drug development, he has served as principal or co-investigator on more than 500 clinical trials and previously led programmes at Memorial Sloan Kettering and Columbia. He helps MIORG assess translational relevance and credible clinical-development routes.

Advisor, Clinical Pathology
Bio

She is the George Holt Chair of Pathology at the University of Liverpool and a senior Consultant Histopathologist, leading the Liverpool Ocular Oncology Research Group. She is President of the Pathological Society of Great Britain and Ireland, and President-Elect of the Royal College of Pathologists, with her College presidency beginning in November 2026. Her international leadership in ocular, molecular and diagnostic pathology gives MIORG exceptional perspective on patient samples, biobanking, pathology and uveal-melanoma translation.

Business Advisory Board

Business and Growth Strategy Advisory Board.

Business & Market Development Lead
Bio

He contributes business and market-development perspective to MIORG’s growth planning. His advice helps connect the company’s preclinical programs with partner needs and commercial positioning.

Fundraising Advisor
Bio

A co-founder and advisor in the Finnish growth-financing ecosystem, he brings experience in investment, commercial development, and founder support. At MIORG, this perspective supports fundraising readiness and investor engagement.

Drug Development Advisor
Bio

An MD, PhD biopharma executive with decades of industry experience and specialist expertise in pharmaceutical medicine, he brings a practical drug-development lens to MIORG. His advice supports the prioritisation and development path of preclinical programs.

Advisor for Growth & Investment Strategy
Bio

A long-standing technology investor and business builder, he has worked with founders, venture-backed companies, fundraising, governance, and exit readiness across international markets. He helps MIORG frame its growth strategy for investors and strategic partners.

Corporate Strategy & Governance · EU Regulatory Affairs
Bio

Educated at the University of Oxford and INSEAD, she has led major digital and commercial transformations as CEO of Tesco.com and Executive Director, Multi-Channel at Marks & Spencer. Her board experience spans NHS England, NHS Improvement, former Chair of NHS Digital, Immunocore, and current independent non-executive roles at Legal & General. She gives MIORG senior-level guidance on governance, strategy, digital transformation and navigating the European healthcare environment.

Scientific Advisory Board

Scientific guidance.

Founder, CEO & Scientific Advisory Board Head
Bio

As Associate Professor (Docent) of Immunology, Academy Research Fellow at the University of Turku, and University Researcher at the University of Helsinki, he brings active academic leadership in cancer immunology to the Scientific Advisory Board. He chairs the Board to ensure MIORG’s programmes remain anchored in patient-derived biology, translational immunology, and realistic preclinical decisions.

Chief Scientific Officer
Bio

His affiliation with the KJCCT at Houston Methodist Research Institute, together with research published from The University of Texas MD Anderson Cancer Center, provides a direct link to leading US translational oncology environments. His expertise in tumor immunology, melanoma models and peptide research supports MIORG’s scientific strategy and experimental prioritisation.

Scientific and Clinical Advisor
Bio

As Professor of Immuno-Oncology at the University of Liverpool and an Adjunct Professor at the La Jolla Institute for Immunology, he combines patient-focused immunology with active translational research and early-phase trial experience. His scientific advisory role provides MIORG a rigorous clinical reference point as programs progress from mechanism to therapeutic hypothesis.

Interested in learning more?

Contact us.

We welcome discussions with scientific, clinical, business, and investment partners.

Contact Us